AE Wealth Management LLC Purchases 7,696 Shares of AbbVie Inc. $ABBV

AE Wealth Management LLC grew its position in AbbVie Inc. (NYSE:ABBV) by 2.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 294,020 shares of the company’s stock after acquiring an additional 7,696 shares during the quarter. AE Wealth Management LLC’s holdings in AbbVie were worth $67,181,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of ABBV. Chelsea Counsel Co. bought a new position in shares of AbbVie during the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC bought a new position in shares of AbbVie during the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie during the 3rd quarter valued at approximately $31,000. Caitlin John LLC bought a new position in shares of AbbVie during the 3rd quarter valued at approximately $33,000. Finally, Legacy Bridge LLC increased its position in shares of AbbVie by 3,800.0% during the 4th quarter. Legacy Bridge LLC now owns 156 shares of the company’s stock valued at $36,000 after purchasing an additional 152 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.3%

ABBV opened at $209.00 on Friday. The company has a market capitalization of $369.55 billion, a price-to-earnings ratio of 88.56, a PEG ratio of 0.74 and a beta of 0.38. AbbVie Inc. has a 12-month low of $168.54 and a 12-month high of $244.81. The business’s fifty day simple moving average is $219.30 and its 200-day simple moving average is $223.67.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ABBV shares. Evercore cut their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Piper Sandler upped their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Guggenheim upped their price objective on AbbVie from $242.00 to $249.00 and gave the company a “buy” rating in a research report on Friday, April 10th. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.00.

Insider Buying and Selling at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.06% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Motley Fool says ABBV is a “no‑brainer” buy on dips, highlighting its high dividend, cash flow and defensive pharma profile as reasons value/dividend investors should buy weakness. Why AbbVie Is a No-Brainer Stock to Buy on the Dip
• Positive Sentiment: AbbVie announced head‑to‑head Phase 4 psoriasis study updates — a potential near‑term clinical catalyst that could influence commercial positioning in immunology if results favor AbbVie’s therapy. AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
• Positive Sentiment: AbbVie kicked off a Phase 1 trial for ABBV‑295 (obesity), signalling a strategic push into the high‑growth weight‑loss market where success could materially expand future revenue streams. AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
• Positive Sentiment: AbbVie paid an upfront of ~$650M to RemeGen for global rights to RC148 — a sizeable bolt‑on that strengthens the company’s oncology/rare disease pipeline (near‑term cash outflow but potential long‑term value). RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
• Neutral Sentiment: Evercore ISI trimmed its price target slightly ($233→$232) but kept an Outperform rating — a minor analyst tweak that maintains institutional conviction. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally
• Neutral Sentiment: Sector pieces and market reports (value stock roundups; thyroid‑eye‑disease market research) include AbbVie as a key player — these reinforce investor awareness but don’t move fundamentals immediately. 1 Value Stock Worth Your Attention and 2 That Underwhelm Thyroid Eye Disease Treatment Market Research Report 2026
• Negative Sentiment: Technicals are a headwind: the stock is trading below both the 50‑day and 200‑day moving averages, which can pressure short‑term sentiment and limit upside until price recovers those levels.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.